999 related articles for article (PubMed ID: 10388979)
1. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.
Toft-Nielsen MB; Madsbad S; Holst JJ
Diabetes Care; 1999 Jul; 22(7):1137-43. PubMed ID: 10388979
[TBL] [Abstract][Full Text] [Related]
2. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.
Näslund E; Barkeling B; King N; Gutniak M; Blundell JE; Holst JJ; Rössner S; Hellström PM
Int J Obes Relat Metab Disord; 1999 Mar; 23(3):304-11. PubMed ID: 10193877
[TBL] [Abstract][Full Text] [Related]
3. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.
Nauck MA; Sauerwald A; Ritzel R; Holst JJ; Schmiegel W
Diabetes Care; 1998 Nov; 21(11):1925-31. PubMed ID: 9802745
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.
Todd JF; Edwards CM; Ghatei MA; Mather HM; Bloom SR
Clin Sci (Lond); 1998 Sep; 95(3):325-9. PubMed ID: 9730852
[TBL] [Abstract][Full Text] [Related]
5. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.
Rachman J; Barrow BA; Levy JC; Turner RC
Diabetologia; 1997 Feb; 40(2):205-11. PubMed ID: 9049482
[TBL] [Abstract][Full Text] [Related]
6. Overnight GLP-1 normalizes fasting but not daytime plasma glucose levels in NIDDM patients.
Willms B; Idowu K; Holst JJ; Creutzfeldt W; Nauck MA
Exp Clin Endocrinol Diabetes; 1998; 106(2):103-7. PubMed ID: 9628239
[TBL] [Abstract][Full Text] [Related]
7. GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions.
Gutniak MK; Larsson H; Sanders SW; Juneskans O; Holst JJ; Ahrén B
Diabetes Care; 1997 Dec; 20(12):1874-9. PubMed ID: 9405910
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment.
Larsen J; Hylleberg B; Ng K; Damsbo P
Diabetes Care; 2001 Aug; 24(8):1416-21. PubMed ID: 11473079
[TBL] [Abstract][Full Text] [Related]
9. Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients.
Nauck MA; Weber I; Bach I; Richter S; Orskov C; Holst JJ; Schmiegel W
Diabet Med; 1998 Nov; 15(11):937-45. PubMed ID: 9827848
[TBL] [Abstract][Full Text] [Related]
10. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.
Nauck MA; Wollschläger D; Werner J; Holst JJ; Orskov C; Creutzfeldt W; Willms B
Diabetologia; 1996 Dec; 39(12):1546-53. PubMed ID: 8960841
[TBL] [Abstract][Full Text] [Related]
11. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.
Lee A; Patrick P; Wishart J; Horowitz M; Morley JE
Diabetes Obes Metab; 2002 Sep; 4(5):329-35. PubMed ID: 12190996
[TBL] [Abstract][Full Text] [Related]
12. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.
Creutzfeldt WO; Kleine N; Willms B; Orskov C; Holst JJ; Nauck MA
Diabetes Care; 1996 Jun; 19(6):580-6. PubMed ID: 8725855
[TBL] [Abstract][Full Text] [Related]
13. Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state.
Egan JM; Meneilly GS; Habener JF; Elahi D
J Clin Endocrinol Metab; 2002 Aug; 87(8):3768-73. PubMed ID: 12161508
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas.
Gutniak MK; Juntti-Berggren L; Hellström PM; Guenifi A; Holst JJ; Efendic S
Diabetes Care; 1996 Aug; 19(8):857-63. PubMed ID: 8842604
[TBL] [Abstract][Full Text] [Related]
15. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study.
Zander M; Madsbad S; Madsen JL; Holst JJ
Lancet; 2002 Mar; 359(9309):824-30. PubMed ID: 11897280
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint A; Raben A; Astrup A; Holst JJ
J Clin Invest; 1998 Feb; 101(3):515-20. PubMed ID: 9449682
[TBL] [Abstract][Full Text] [Related]
17. Additive effects of glucagon-like peptide 1 and pioglitazone in patients with type 2 diabetes.
Zander M; Christiansen A; Madsbad S; Holst JJ
Diabetes Care; 2004 Aug; 27(8):1910-4. PubMed ID: 15277416
[TBL] [Abstract][Full Text] [Related]
18. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.
Vilsbøll T; Krarup T; Madsbad S; Holst JJ
Regul Pept; 2003 Jul; 114(2-3):115-21. PubMed ID: 12832099
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
Vilsbøll T; Toft-Nielsen MB; Krarup T; Madsbad S; Dinesen B; Holst JJ
Diabetes Care; 2000 Jun; 23(6):807-12. PubMed ID: 10841001
[TBL] [Abstract][Full Text] [Related]
20. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2.
Gutzwiller JP; Drewe J; Göke B; Schmidt H; Rohrer B; Lareida J; Beglinger C
Am J Physiol; 1999 May; 276(5):R1541-4. PubMed ID: 10233049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]